Skip to main content
SpringerLink
Log in

Significance of docetaxel-based chemotherapy as treatment for metastatic castration-resistant prostate cancer in Japanese men over 75 years old

  • Urology - Original Paper
  • Published:
International Urology and Nephrology Aims and scope Submit manuscript

Abstract

Objectives

The objective of this study was to evaluate the significance of docetaxel-based chemotherapy in elderly Japanese men with metastatic castration-resistant prostate cancer (CRPC).

Materials and methods

This study included a total of 159 consecutive patients aged ≥75 years with mCRPC who were treated with docetaxel-based chemotherapy. The efficacy and tolerability of this therapy were retrospectively analyzed.

Results

In these 159 patients, the median age and prostate-specific antigen (PSA) level before docetaxel-based chemotherapy were 78 years and 44.0 ng/ml, respectively. Of these patients, 42 (26.4 %) and 117 (73.6 %) received docetaxel as a weekly (30 mg/m2) and 3-weekly (70 mg/m2) regimen, respectively, and estramustine was administered combining with docetaxel in 77 (48.4 %). Following docetaxel-based chemotherapy, PSA declined in 118 patients (74.3 %), including 87 (54.6 %) achieving a PSA decline ≥50 %, and the median progression-free survival and overall survival (OS) were 2.9 and 23.2 months, respectively. Of several factors examined, univariate analysis identified performance status (PS), significant clinical pain, bone metastasis, schedule of treatment, treatment cycle, and PSA response as significant predictors of OS, of which only PS, treatment cycle, and PSA response appeared to be independently associated with OS on multivariate analysis. The major grade 3–4 toxicities were myelosuppression, including neutropenia, anemia, and thrombocytopenia in 78 (49.1 %), 22 (13.8 %), and 14 (8.8 %), respectively.

Conclusions

These findings suggest that docetaxel-based chemotherapy is clinically feasible in Japanese men aged ≥75 years with mCRPC considering the cancer control as well as safety associated with this therapy.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3

Similar content being viewed by others

References

  1. Matsuda T, Marugame T, Kamo K, Katanoda K, Ajiki W, Sobue T (2011) Cancer incidence and incidence rates in Japan in 2005: based on data from 12 population-based cancer registries in the Monitoring of Cancer Incidence in Japan (MCIJ) project. Jpn J Clin Oncol 41:139–147

    Article  PubMed  Google Scholar 

  2. Cancer Registration Committee of the Japanese Urological Association (2005) Clinicopathological statistics on registered prostate cancer patients in Japan: 2000 report from the Japanese Urological Association. Int J Urol 12:46–61

    Article  Google Scholar 

  3. Donkena KV, Yuan H, Young CY (2010) Recent advances in understanding hormonal therapy resistant prostate cancer. Curr Cancer Drug Targets 10:402–410

    Article  PubMed  CAS  Google Scholar 

  4. Beltran H, Beer TM, Carducci MA et al (2011) New therapies for castration-resistant prostate cancer: efficacy and safety. Eur Urol 60:279–290

    Article  PubMed  CAS  Google Scholar 

  5. Droz JP, Balducci L, Bolla M et al (2010) Management of prostate cancer in older men: recommendations of a working group of the International Society of Geriatric Oncology. BJU Int 106:462–469

    Article  PubMed  Google Scholar 

  6. Tannock IF, de Wit R, Berry WR et al (2004) Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 351:1502–1512

    Article  PubMed  CAS  Google Scholar 

  7. Petrylak DP, Tangen CM, Hussain MH et al (2004) Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med 351:1513–1520

    Article  PubMed  CAS  Google Scholar 

  8. Ide H, Kikuchi E, Kono H et al (2010) Docetaxel in combination with prednisolone for hormone refractory prostate cancer. Jpn J Clin Oncol 40:79–84

    Article  PubMed  Google Scholar 

  9. Matsumoto A, Inoue A, Yokoi S et al (2009) Evaluation of docetaxel plus estramustine in the treatment of patients with hormone-refractory prostate cancer. Int J Urol 16:687–691

    Article  PubMed  CAS  Google Scholar 

  10. Naito S, Tsukamoto T, Koga H et al (2008) Docetaxel plus prednisolone for the treatment of metastatic hormone-refractory prostate cancer: a multicenter phase II trial in Japan. Jpn J Clin Oncol 38:365–372

    Article  PubMed  CAS  Google Scholar 

  11. Takaha N, Okihara K, Kamoi K et al (2011) Feasibility of tri-weekly docetaxel-based chemotherapy for elderly patients (age 75 and older) with castration-resistant prostate cancer. Urol Int 87:263–269

    Article  PubMed  CAS  Google Scholar 

  12. Italiano A, Ortholan C, Oudard S et al (2009) Docetaxel-based chemotherapy in elderly patients (age 75 and older) with castration-resistant prostate cancer. Eur Urol 55:1368–1375

    Article  PubMed  CAS  Google Scholar 

  13. Takechi H, Ito K, Yamamoto T, Miyakubo M, Ohi M, Suzuki K (2008) Prostate-specific antigen kinetics in screen-detected prostate cancer in Japan. Urology 72:1111–1115

    Article  PubMed  Google Scholar 

  14. Maekawa K, Harakawa N, Yoshimura T et al (2010) CYP3A4*16 and CYP3A4*18 alleles found in East Asians exhibit differential catalytic activities for seven CYP3A4 substrate drugs. Drug Metab Dispos 38:2100–2104

    Article  PubMed  CAS  Google Scholar 

  15. Misumi T, Yamamoto Y, Murakami T et al (2010) Genetic alterations at 13q14 may correlate with differences in the biological behavior of prostate cancer between Japanese and Caucasian men. Urol Int 84:461–466

    Article  PubMed  CAS  Google Scholar 

  16. Phan VH, Moore MM, McLachlan AJ, Piquette-Miller M, Xu H, Clarke SJ (2009) Ethnic differences in drug metabolism and toxicity from chemotherapy. Expert Opin Drug Metab Toxicol 5:243–257

    Article  PubMed  CAS  Google Scholar 

  17. Miyake H, Sakai I, Terakawa T, Harada KI, Fujisawa M. Oncological outcome of docetaxel-based chemotherapy for Japanese men with metastatic castration-resistant prostate cancer. Urol Oncol (in press)

  18. Armstrong AJ, Garrett-Mayer ES, Yang YC, de Wit R, Tannock IF, Eisenberger M (2007) A contemporary prognostic nomogram for men with hormone-refractory metastatic prostate cancer: a TAX327 study analysis. Clin Cancer Res 13:6396–6403

    Article  PubMed  CAS  Google Scholar 

  19. Armstrong AJ, Tannock IF, de Wit R, George DJ, Eisenberger M, Halabi S (2010) The development of risk groups in men with metastatic castration-resistant prostate cancer based on risk factors for PSA decline and survival. Eur J Cancer 46:517–525

    Article  PubMed  CAS  Google Scholar 

  20. ten Tije AJ, Verweij J, Carducci MA et al (2005) Prospective evaluation of the pharmacokinetics and toxicity profile of docetaxel in the elderly. J Clin Oncol 23:1070–1077

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Division of Urology, Kobe University Graduate School of Medicine, 7-5-1 Kusunoki-cho, Chuo-ku, Kobe, 650-0017, Japan

    Hideaki Miyake, Iori Sakai, Ken-ichi Harada, Mototsugu Muramaki & Masato Fujisawa

Authors
  1. Hideaki Miyake
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Iori Sakai
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Ken-ichi Harada
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Mototsugu Muramaki
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Masato Fujisawa
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Hideaki Miyake.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Miyake, H., Sakai, I., Harada, Ki. et al. Significance of docetaxel-based chemotherapy as treatment for metastatic castration-resistant prostate cancer in Japanese men over 75 years old. Int Urol Nephrol 44, 1697–1703 (2012). https://doi.org/10.1007/s11255-012-0223-z

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11255-012-0223-z

Keywords

Search

Navigation